Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme

Background Bundle branch block (BBB) is a powerful independent predictor of cardiovascular mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). The prognostic implications in HF with preserved systolic function (HF-PSF) are less well understood. Method...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2007-05, Vol.9 (5), p.510-517
Main Authors: Hawkins, Nathaniel M., Wang, Duolao, McMurray, John J.V., Pfeffer, Marc A., Swedberg, Karl, Granger, Christopher B., Yusuf, Salim, Pocock, Stuart J., Östergren, Jan, Michelson, Eric L., Dunn, Francis G.
Format: Article
Language:English
Subjects:
Aged
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Benzimidazoles - therapeutic use
bundle branch block
Bundle-Branch Block - epidemiology
Bundle-Branch Block - etiology
Bundle-Branch Block - physiopathology
Bundle-Branch Block - prevention & control
candesartan
Cardiac and Cardiovascular Systems
Double-Blind Method
electrocardiogram
Electrocardiography
Female
Follow-Up Studies
heart failure
Heart Failure - complications
Heart Failure - drug therapy
Heart Failure - epidemiology
Heart Failure - physiopathology
Humans
Kardiologi
left ventricular systolic dysfunction
Male
Medicin och hälsovetenskap
Middle Aged
Multivariate Analysis
Predictive Value of Tests
preserved systolic function
Prevalence
Prognosis
Proportional Hazards Models
Randomized Controlled Trials as Topic
Risk Factors
Stroke Volume
Survival Analysis
Tetrazoles - therapeutic use
Treatment Outcome
Ventricular Dysfunction, Left - drug therapy
Ventricular Dysfunction, Left - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Bundle branch block (BBB) is a powerful independent predictor of cardiovascular mortality in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). The prognostic implications in HF with preserved systolic function (HF-PSF) are less well understood. Methods The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme randomised 7599 patients with symptomatic HF to receive candesartan or placebo. The primary outcome comprised cardiovascular death or HF hospitalisation. The relative risk conveyed by BBB relative to a normal electrocardiogram was examined. Results The prevalence of BBB was significantly lower in patients with preserved compared with reduced systolic function (CHARM-Preserved 14.4%, Alternative 29.6%, Added 30.5%), p
ISSN:1388-9842
1879-0844
DOI:10.1016/j.ejheart.2006.11.006